Floatz logo

ANTI-PD-L1 MONOCLONAL ANTIBODY SHR-1316

Triple-Negative Breast Carcinoma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.monoclonal_antibodyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

ANTI-PD-L1 MONOCLONAL ANTIBODY SHR-1316 is also rated in:

small cell lung carcinomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →
non-small cell lung carcinomaActive
B
Indicative · Phase 3
62 / 100
View asset →
cancerActive
CCC
Indicative · Phase 2
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →